

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

gov.uk/mhra

Decision Cover Letter

Decision of the licensing authority to:

accept change(s) to the agreed paediatric investigation plan and to the deferral.

MHRA-100921-PIP01-23-M01

Scope of the Application

Active Substance(s)

AVATROMBOPAG

Condition(s)

Treatment of Idiopathic Thrombocytopenia Purpura, Treatment of Thrombocytopenic Purpura
Secondary to Liver Disease

Pharmaceutical Form(s)

Film-coated tablet; Powder for Oral suspension

Route(s) of Administration

ORAL USE

Name / Corporate name of the PIP applicant

Swedish Orphan Biovitrum AB

Basis for the Decision

Pursuant to the Human Medicines Regulations 2012, Swedish Orphan Biovitrum AB submitted to the licensing authority on 13/03/2023 12:50 GMT an application for a Modification

The procedure started on 07/08/2023 18:58 BST

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to accept change(s) to the agreed paediatric investigation plan and to the deferral

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

MHRA
10 South Colonnade
Canary Wharf
London
E14 4PU
United Kingdom

[gov.uk/mhra](https://www.gov.uk/mhra)

Final Decision Letter

MHRA-100921-PIP01-23-M01

Of 05/09/2023 08:29 BST

On the adopted decision for AVATROMBOPAG (MHRA-100921-PIP01-23-M01) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on modification of a paediatric investigation plan (including modification of a waiver or deferral included in that paediatric investigation plan)

This decision applies to a Modification for AVATROMBOPAG, Film-coated tablet; Powder for Oral suspension , ORAL USE .

This decision is addressed to Swedish Orphan Biovitrum AB, Tomtebodavägen 23A, Stockholm, SWEDEN, 11276

ANNEX I

1. Waiver

1.1 Condition:

Condition 1: Treatment of Idiopathic Thrombocytopenic Purpura. The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 1 year of age. Pharmaceutical form(s): Film-coated tablet, Powder for Oral suspension Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset(s). Condition 2: Treatment of Thrombocytopenic Purpura Secondary to Liver Disease. The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 18 years of age. Pharmaceutical form(s): Film-coated tablet, Powder for Oral suspension Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan:

2.1 Condition(s):

Treatment of Idiopathic Thrombocytopenic Purpura.

2.2 Indication(s) targeted by the PIP:

Treatment of thrombocytopenia in patients aged 1 year to less than 18 years with chronic immune (idiopathic) thrombocytopenic purpura (ITP), who have had insufficient response to at least one prior ITP treatment.

2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 1 year to less than 18 years of age.

2.4 Pharmaceutical Form(s):

Film-coated tablet Powder for Oral suspension

2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	2	Study 1 Development of an age appropriate pharmaceutical form for oral use. Study 2 (AVA-PED-101) Bioavailability study of the tablet for oral suspension in healthy adults.
Non-Clinical Studies	2	Study 3 (NC1) 4-week dose range finding oral toxicity study in juvenile rats. Study 4 (NC2) 10-week oral toxicity study in juvenile rats followed by a 4-week recovery period.
Clinical Studies	1	Study 5 (AVA-PED-301) Randomised, double-blind, placebo-controlled, parallel group trial with open-label extension phase to assess efficacy, PK/PD, and safety of avatrombopag (maleate) (E5501) in children with chronic idiopathic thrombocytopenic purpura.
Extrapolation, Modeling & Simulation Studies	1	Study 6 (AVA-PKPD-PED-ITP-003) This study was added during modification EMEA-001136-PIP01-11-M01. Population Pharmacokinetic / Pharmacodynamic

		(PopPKPD) study to predict initial paediatric doses to be used in further clinical studies.
Other Studies	0	Not available.
Other Measures	0	Not available.

3. Follow-up, completion and deferral of a PIP:

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	31/12/2025
Deferral of one or more studies contained in the paediatric investigation plan:	Yes